Drug Treatment
ApprovedSmall molecule
Drug Treatment is one of 267 small molecule programs targeting Arrhythmia. It is currently in Approved.
8
Indications
11
Total Trials
2
Active Trials
266
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
376 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Drug Treatment
BBiosense Webster, Inc.
Approved
Calquence
AstraZenecaPreclinical
Calan
VVal Adams
Preclinical
Imbruvica
PPharmacyclics LLC.
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Anticoagulants
SanofiPreclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ankylosing Spondylitis1 trial
Arrhythmia1 trial
Arrhythmia Cohort Study
Not yet recruiting·—··NCT07123896·10,000 enrolled
6 more indications
Dermatomyositis1 trial
Depression1 trial
Bipolar Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Drug Treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- BBiosense Webster, Inc.